After rising 25% in one month, the US biotech and biopharmaceutical sector sharply fell on Friday.

The U.S. biotech and biopharma sector saw a large-scale sell-off on Friday. The big gains accumulated beforehand triggered concentrated profit-taking, with the sector’s benchmark ETF falling 4% on the day.

Moderna shares fell 11% to $68.50, ImmunityBio dropped 8% to $8.16, and Sarepta Therapeutics fell 8% to $18.84. None of the three companies had any negative news that triggered this decline. Market generally interpreted this pullback as profit-taking after rallying to elevated levels. At the same time, there were clear signs of sector rotation—money flowed from high-beta biotech stocks to defensive, large-cap pharmaceutical companies.

Profit-taking dominated this round of sell-off

This downturn came after the three companies surged sharply earlier this year. As of Thursday’s close, Moderna’s year-to-date gain was 160%, while ImmunityBio’s year-to-date gain was even higher at 348%. Against this backdrop, no individual stock showed fundamental, downside-moving news.

From the latest fundamentals, developments for the relevant companies have actually been relatively positive. ImmunityBio’s revenue in Q1 reached $44.21 million, up 168% year over year, and ANKTIVA’s sales volume also rose 168% over the same period. Sarepta Therapeutics just received an upgraded rating from Wolfe Research to “Outperform the Market,” with a $27 price target, implying 34% upside from Thursday’s closing price. Moderna’s Q1 revenue was $389 million, exceeding market consensus by 65%, and management also reiterated that full-year revenue growth could be as high as 10%.

With no negative catalysts and fundamentals remaining comparatively steady, the logic behind this drop points to a single factor—concentrated profit-taking after a parabolic rally.

Large pharma firms held up relatively better, with clear rotation signals

Friday’s sector differentiation provided important clues about fund flows. Eli Lilly’s year-to-date gain is still 10%, and Johnson & Johnson’s year-to-date gain is 24%, with both falling far less than high-beta biotech stocks.

This price gap reveals a clear rotation logic: funds left biotech small caps that are not yet profitable and have higher volatility, and instead stayed with large pharmaceutical companies with stronger defensive characteristics and more stable earnings power. This is not a systematic de-risking from the entire pharma sector, but more like an active adjustment in risk appetite.

XBI uses an equal-weight construction method, and Moderna, ImmunityBio, and Sarepta are all constituent stocks in its holdings. Friday’s overall decline suggests the adjustment was not driven by just one lagging stock, but rather represented a broad pullback at the sector level.

It is worth noting that even after Friday’s sharp drop, XBI’s cumulative gain over the past 12 months is still as high as 78%. This figure suggests this adjustment is more like normal volatility after a rapid rise, rather than the start of a trend reversal. However, XBI’s equal-weight feature also implies that once multiple stocks within the sector pull back in sync, the ETF’s declines are often amplified.

Moderna’s long/short disagreement intensifies

Among today’s three heavily down stocks, Moderna’s long-versus-short debate is the most representative.

The bull case centers on pipeline progress: the FDA decision date (PDUFA) for its influenza vaccine mRNA-1010 is set for August 5; in addition, there are multiple branded products including Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX; and management has set a year-end target for cash holdings of $4.5 billion to $5.0 billion, giving the company ample room for operations.

The bear case focuses on valuation and financial pressure: Moderna’s share price is still down 71% compared with five years ago; GAAP net loss in Q1 was $1.34 billion; cash burn remains at elevated levels; and analysts’ consensus target prices are clearly below the current share price. On Friday, the stock fell by more than 10% in a single day, directly reflecting its high-beta profile and the two-way risks that come with it.

What to watch next

In the near term, the market’s focus is whether XBI can stabilize before the close; if the selling accelerates, it would mean there is further room for sector rotation to play out. For Moderna, the August 5 FDA approval result for its influenza vaccine is the next important catalyst with a clear timeline.

Overall, this sharp drop in the biotech and biopharma sector looks closer to a technical pullback after a historic rally, rather than a substantive deterioration in fundamentals. For investors holding the aforementioned stocks, how to strike a balance between high-beta exposure and potential catalysts may be the most important question to consider right now.

Risk warning and disclaimer

        The market involves risks; investing requires caution. This article does not constitute personal investment advice, and it has not considered any individual users’ special investment objectives, financial situations, or needs. Users should consider whether any opinions, viewpoints, or conclusions in this article align with their specific circumstances. Investing based on this is at your own risk and responsibility.